RT Journal Article
SR Electronic
T1 Declines in life expectancy following the COVID-19 pandemic in provinces of Spain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.15.21255545
DO 10.1101/2021.04.15.21255545
A1 Sergi Trias-Llimós
A1 Amand Blanes
A1 Manuel Franco
A1 Usama Bilal
A1 Tim Riffe
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.04.15.21255545.abstract
AB The COVID-19 pandemic has impacted population health on a global scale. Most of the studies on mortality impacts are at national level, while broad evidence exists on heterogeneous COVID-19 incidence across regions and within countries. Using Spanish data for 2020, we estimate life expectancy changes in 2020 compared with the 2017-19 period in 50 Spanish provinces. We visualize longer-term trends (1990-2020), and compare the robustness of our province-specific results with cumulative COVID-19 incidence using regional data from the Spanish ENECOVID seroprevalence study. In 2020 there was a 1.2 and 1.1 year drop in life expectancy for men and women in Spain, but this impact was heterogeneous across regions. For men these losses were highest in the province of Segovia (−3.5 years decline), while for women the highest drop was observed in Salamanca (−2.8 years decline). Life expectancy actually increased in Santa Cruz de Tenerife (+1.1 and +0.6 years for men and women, respectively). Declines in life expectancy in 2020 were also highly correlated with the cumulative seroprevalence through November 2020 (ρ=0.80 and 0.77 in men and women, respectively). Monitoring regional life expectancy dynamics provide valuable and granular information on the heterogeneous impacts of the pandemic on health at the population level. Similar exercises in other European countries may reveal insightful geographic patterns in mortality impacts in COVID-19 pandemic years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSTL acknowledges research funding from the Juan de la Cierva-Formacion program of the Spanish Ministry of Science and Innovation (FJC2019-039314-I) and from the HEALIN project led by Inaki Permanyer (ERC-2019-COG agreement No 864616). UB was supported by the Office of the Director of the National Institutes of Health under award number DP5OD26429.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLinks to the original data sources can be found in Supplementary Material. Data and analysis code can be found at: https://osf.io/duqwx/